Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LTRN
LTRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LTRN News
LANTERN PHARMA STOCK RISES 7.1% FOLLOWING FDA APPROVAL FOR CHILD BRAIN CANCER TREATMENT TRIAL
3d ago
moomoo
Lantern Pharma CEO Panna Sharma Remains in Position, Addresses False Claims
3d ago
Newsfilter
LANTERN PHARMA AFFIRMS PANNA SHARMA REMAINS PRESIDENT AND CEO; WARNS INVESTORS ABOUT INACCURATE THIRD-PARTY REPORT
3d ago
moomoo
Lantern Pharma Receives FDA Clearance for STAR-001 Pediatric Trial
3d ago
NASDAQ.COM
Lantern Pharma Receives FDA IND Approval for STAR-001
3d ago
stocktwits
FDA Approves STAR-001 for Pediatric CNS Cancer Trial
3d ago
Newsfilter
RedChip Releases AI Investor Conference Replays
3d ago
Yahoo Finance
Lantern Pharma to Host Q4 2025 Earnings Webcast on March 30
Mar 23 2026
Newsfilter
Growth Prospects for the EGFR-NSCLC Market Analyzed
Feb 11 2026
Newsfilter
Lantern Pharma CEO to Present at Glioblastoma Summit
Feb 10 2026
Businesswire
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
Dec 27 2025
Yahoo Finance
Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors
Dec 03 2025
NASDAQ.COM
Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.
Oct 28 2025
Newsfilter
Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025
Oct 24 2025
Newsfilter
Lantern Pharma Reports Positive Safety and Initial Efficacy Results for Cancer Drug in Phase 1 Trial
Sep 16 2025
Yahoo Finance
Lantern Pharma Reports Successful Phase 1a Study of LP-184 in Advanced Solid Tumors, Achieving All Primary Endpoints
Sep 16 2025
NASDAQ.COM
Show More News
